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Abstract
Objective: To establish the prevalence of unmet need for spasticity management in care home
residents in two counties of the United Kingdom
Design: cross-sectional observational study with a 6-month follow-up arm for participants with
identified unmet needs
Setting: 22 care homes in Derbyshire and Nottinghamshire
Subjects: 60 care home residents with upper motor neuron syndrome-related spasticity
Interventions: No intervention. When unmet needs around spasticity management were identified,
the participant’s general practitioner was advised of these in writing.
Main measures: Resistance to passive movement scale to assess spasticity; recording of: a) presence
of factors which may aggravate spasticity, b) potential complications of spasticity, c) spasticity-
related needs, d) current interventions to manage spasticity. Two assessors judged the presence or
absence of needs for spasticity management and whether these needs were met by current care.
Results: 14/60 participants had no spasticity-related needs; 46/60 participants had spasticity-related
needs and of these 11/60 had needs which were being met by current care. 35/60 participants had
spasticity-related needs at baseline which were not being met by their current care. These most
frequently related to the risk of contracture development or problems with skin hygiene or integrity
in the upper limb. Six participants had one or more pressure sores and 35 participants had one or
more established joint contractures.
31 participants were available for follow-up. Informing general practitioners of unmet needs
resulted in no change to spasticity management in 23/31 cases.
Conclusion: Care home residents in this study had high levels of unmet need for spasticity
management.
Keywords: spasticity management, care home residents, unmet need, upper limb
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Introduction
Spasticity is a common and often disabling consequence of a variety of upper motor neuron
syndrome conditions, including stroke, multiple sclerosis, and brain and spinal cord injury (1-4). It is
characterised by a velocity-dependent increase in muscle tone. It can cause pain and muscle spasms,
and can contribute to a range of complications, including contractures and pressure ulcers (5-7). As a
consequence, patients with spasticity may experience reduced quality of life and are subject to
higher health and social care costs (8, 9).
Optimal treatment of spasticity involves multidisciplinary input, addressing the primary impairment,
reducing factors recognised to precipitate or exacerbate spasticity and managing the risk of
developing secondary complications (10). However, not all populations can access such specialist
multidisciplinary services, leading to inequitable treatment across patient groups. One arguably
“neglected” patient population is those people resident in care homes. In the United Kingdom, care
homes are divided into two categories – i) residential homes – where people receive help with
personal care such as washing and dressing and ii) nursing homes – where residents have more
complex needs and require help with personal care and input from a qualified nurse (11). We are
unaware of any studies reporting the prevalence of spasticity in care homes in the United Kingdom
but studies from the United States of America and the Netherlands provide estimates around 15-
20% (12, 13).
It is known that around 25% of United Kingdom care home residents have had a previous stroke
(14), the most common cause of spasticity, and that around 13% of stroke survivors are left with
disabling spasticity (15). Given the current population of United Kingdom care homes of 421,000
(16), one could estimate that up to 14,000 United Kingdom care home residents may have
problematic post-stroke spasticity. Unfortunately, care home residents have been shown to have
2less access to healthcare services (including rehabilitation services) than people living in the
community (17, 18), despite often having higher levels of need (19). A study from the Netherlands
found that out of 77 care home residents with central nervous system disorders, 56 had spasticity,
and of those 56, 20 had some level of clinical need which was not being met by their current care
(13). A better understanding is required of the range and level of spasticity-related needs
experienced by care home residents in the United Kingdom in order to assess if further targeted
interventions are warranted.
The primary objective of this study was to establish the prevalence of unmet need relating to
spasticity management in a sample of care home residents with spasticity in the East Midlands,
United Kingdom. We also sought to investigate whether highlighting these unmet needs to a
participant’s general practitioner resulted in changes in spasticity management.
3Methods
We conducted a cross-sectional, observational study of care home residents in two regions of the
East Midlands, United Kingdom, to explore the prevalence of needs for spasticity management and
to find out how often these needs were met. The study protocol was approved by Nottingham 1
Research Ethics Committee (REC 12/EM/0060).
Care homes were identified from local directories (Derbyshire Care Services Directory 2013/2014
and Nottinghamshire County Council Care and Support Services Directory 2013/2014), and their
managers were invited to participate in the study by letter followed up by telephone call (see figure
1). Care home managers who did not respond to the letter were telephoned to ascertain their level
of interest. Once a care home manager had agreed to participate in the study, they or a nominated
senior member of nursing staff at the care home were identified as liaison for the study. This
member of staff had responsibility for suggesting potential participants to study staff, based on
medical history and clinical presentation.
Care homes that specialised in caring for residents with neurological conditions as well as those that
did not were both invited to participate in the study. However, to avoid a disproportionate number
of participants being recruited from specialist neurological care homes we decided to recruit no
more than 10 participants from each care home. In cases where more than 10 potential participants
were identified by care home staff, the potential participants were assigned a number in sequence
(based on their surnames, in alphabetical order), and then a random number generator was used to
select 10 participants.
Participants were invited into the study based on the following eligibility criteria:
 Inclusion criteria: upper motor neuron lesion with subsequent spasticity; aged over 16;
permanently resident in care home
4 Exclusion criteria: primary diagnosis of dementia or Parkinson’s disease; on end of life care
pathway; unable to gain consent or assent; absence of spasticity on examination
Participants with mental capacity to do so provided written informed consent. Participants who
lacked capacity and who could not give consent were recruited if informed assent was obtained
from a consultee, such as a family member, acting on the participant’s behalf.
Participants were recruited and assessed between September 2014 and August 2015 by members of
the study team (LE, BE). All participants meeting the eligibility criteria underwent assessment by a
neurological physiotherapist (BE) and rehabilitation medicine specialist registrar (LE) using an
assessment proforma. The assessment proforma was developed collaboratively by a focus group of
clinicians consisting of a neurophysiotherapist, two rehabilitation medicine consultants, one stroke
medicine consultant and one rehabilitation medicine specialty registrar. All group members were
experienced in treating patients with adult spasticity and had worked in spasticity management for
between 4 and 16 years. The proforma was based on published literature, including the then current
United Kingdom Royal College of Physicians clinical guidelines for the management of spasticity in
adults with botulinum toxin (20). The proforma was designed to gain a snapshot of each participant’s
clinical presentation, their need for management of spasticity and whether this need was being met.
Data collected in the proforma included:
 Participant demographic and clinical details such as medical diagnosis causing spasticity, co-
morbid conditions, language impairment, method of transfer (Table 1)
 Assessment of cognitive function using the Abridged Mental Test-4, a rapidly administered,
4-question screening test for cognitive impairment, scored between 0 (lowest score
indicating greatest impairment) and 4 (highest score indicating least impaired) (21) (Table 1)
5 Level of independence in activities of daily living using the Barthel Index (a 10 item scoring
system around different activities of daily living, with scores ranging from 0 (totally
dependent) to 10 (totally independent) (22) (Table 1)
 Presence of spasticity assessed by REPAS in upper and lower limbs. REPAS is a summary
rating scale for REsistance to PASsive movement, with a total score and regional body
subtest scores, based on the Ashworth Scale with additional guidelines for test
administration and scoring. The REPAS measures resistance in 8 upper limb and 5 lower limb
joints, scored between 0-4 at each joint, with total scores ranging between 0 (no spasticity
identified at any joint) to 104 (increased tone limiting passive movement to less than ¼ of
that expected at each joint assessed) (23) (Table 1)
 Presence of complications which could result from the presence of spasticity such as
pressure sores, contractures or pain (Table 1)
 Presence of noxious stimuli known to exacerbate spasticity (Table 2)
 Current treatments or interventions being received by participants that could treat spasticity
and influence the clinical needs identified (Table 3)
 Assessment of clinical need for spasticity management (such as tightly flexed fingers which
could result in breakdown of skin and difficulty with washing hand). When there was a need
for spasticity management but no intervention in place this was designated as an “unmet
need” for spasticity management (Table 4).
The assessment pro-forma was trialled with a small number of patients in a spasticity management
clinic in Nottingham to ensure the form was easy to use and captured relevant information.
The study assessment team assessed the participants together and reached agreement on any areas
of subjective opinion (e.g. whether a need was currently met or unmet). Assessments were carried
out in the care homes, with permission to access the care homes being granted by senior care home
6staff. Data were collected from the participants’ care home records (e.g. details of medications),
from direct questioning of participants / consultee / care home staff (e.g. Barthel index) and from
examination by the study team (e.g. presence and severity of spasticity).
When unmet needs were identified, a letter was written to the participant’s general practitioner to
inform him or her of the nature of the needs. After six months, the care home was contacted via
telephone to ask the nominated senior member of staff about any alterations made to spasticity-
related management plans during the intervening period to address any of the unmet needs
highlighted (for example changes to medication appropriate to the needs highlighted, therapy input,
equipment provision or specialist referrals).
Data handling and statistical analysis
A target sample size of 97 participants with spasticity was calculated using nQuery Advisor 6.01
based on an assumption that the proportion of participants with unmet needs for spasticity
management out of those with spasticity was 50% with a precision of +/-10% at 95% Confidence
Interval.
All statistical analyses were performed by the study statistician using Stata/IC v11.0. The primary
outcome (proportion of participants with spasticity who had unmet needs) was presented with its
95% Confidence Interval. Continuous variables (age, Abbreviated Mental Test score, Resistance to
Passive Movement Scale, Barthel score, number of noxious stimuli, total number of interventions)
were tested for normality using skewness and kurtosis tests and by reviewing histogram plots. The
normally distributed continuous variables were then presented as means with 95% Confidence
Intervals for the “Spasticity” population, the “Spasticity with Needs” population and the “Spasticity
7with Unmet Needs” population, which were then compared using the p-value of an Analysis of
Variance test to assess statistically significant difference between the three groups.
Those continuous variables that were not distributed normally were presented as medians (with
Interquartile Ranges) for the same three populations, which were then compared using the p-value
of a Kruskal-Wallis test to assess statistically significant difference between the three groups. The
categorical variables (gender, type of care home, diagnosis, co-morbidities, mobility, method of
transfer, language impairment, muscle spasms, noxious stimuli, intervention types) were presented
as frequencies (with percentages) for the same three populations, which were then compared using
the p-value of a chi-squared test to assess statistically significant differences between the three
groups. Fisher’s Exact tests were used to assess if having unmet spasticity needs was independent of
each categorical variable. Spearman’s and Pearson’s correlation coefficients were used to assess if
having unmet spasticity needs was correlated with each continuous variable.
8Results
Recruitment and retention of care homes and participants through the study are summarised in the
flow chart in Figure 1. A total of 438 care homes were invited to participate in the study. The
majority declined (399/438 = 91%). A total of 39 care homes agreed to participate and 386 residents
were screened for possible inclusion. A small number of residents declined to participate and three
were on the end-of-life care pathways. However, the most common reason for exclusion was
because the resident did not have an upper motor neuron syndrome, and care home staff had
misidentified joint stiffness (commonly due to arthritis) as spasticity. Unfortunately, the exact
numbers of individuals who were excluded due to each factor are not available.
In total, 60 participants with spasticity met the inclusion criteria and underwent full assessment.
Demographic and clinical details of the participants are presented in Table 1. Diagnoses of
participants were as follows: stroke (29 participants), brain injury (11), multiple sclerosis (7), cerebral
palsy (6), spinal cord injury (3), spinocerebellar ataxia (2), brain metastases (1), progressive
supranuclear palsy (1).
The participants were a dependent population, with only two participants able to walk, whilst the
remainder used a wheelchair (52) or were entirely restricted to bed (six). Four participants could
transfer independently, whilst the remainder needed assistance or transfer aids.
“Noxious stimuli” which act as aggravating factors for spasticity, were present in 45/60 (75%)
participants. More than one noxious stimulus was present in several participants with a range of 0-5.
See Table 2 for details.
Complications which could result from the presence of spasticity were present in many participants.
Joint contractures were identified in 35 participants (35/60 = 58%). Pressure ulcers were identified in
six participants (6/60 = 10%). A total of nine pressure ulcers were present in these six participants –
three sacral, two on the heel, and one each at elbow, shin, ankle and antecubital fossa. Five ulcers
9were grade 1 (non-blanchable erythema); two were grade 2 (partial thickness) and two could not be
classified as the base was not visible. In the opinion of the assessors, spasticity was felt to have
contributed to the development or presence of the pressure ulcer in all but one case.
Spasticity-related interventions received by participants are shown in Table 3. Interventions most
commonly provided were podiatric review (56/60 = 93%), appropriate seating (48/60 = 80%),
provision of a cushion (48/60 = 80%) and regular analgesia (46/60 = 77%).
Spasticity-related needs were identified in 46/60 (77%) participants. In 9 of these cases, all needs
were being met by current care. However, in the remaining 35, spasticity-related needs were not
being met by current care (see Table 4), giving a prevalence of participants with spasticity who had
unmet needs at baseline of 59%, with 95% Confidence Intervals of 46-72%. Mean (SD) of number of
needs per participant in the study population was 4.9 (3.7). Mean number of unmet needs was 2.4
(2.7) per participant. Needs relating to upper limb were more frequently identified than needs
relating to lower limb or trunk.
The most frequent unmet need relating to spasticity related to management and prevention of
contracture and related impact on passive care needs. Contracture avoidance and management in
the upper limb was the most commonly identified unmet need (26/60 participants (43%)), followed
by management of skin hygiene and integrity in the hand (22/60 (37%)). Unmet needs relating to
management and prevention of contracture in the lower limb were slightly less common than in
upper limb, occurring in 17 participants (28%).
In contrast, certain spasticity-related needs were regularly met. Difficulty with dressing due to the
presence of spasticity was a need in around half of participants (lower limb 25/60 (42%), upper limb
34/60 (57%)). However this need was usually met by care home staff, with no additional benefit
considered likely from further management, resulting in a low level of unmet need (lower limb 2/60
(3%), upper limb 3/60 (5%)).
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Analysis with correction for multiple comparisons revealed a weakly positive correlation between
total number of unmet needs and age (Pearson’s correlation co-efficient 0.395; p=0.009). There was
a weak negative correlation between the total number of unmet needs and the number of
spasticity-related interventions (Pearson’s correlation co-efficient -0.364; p=0.027) (see Figure 2).
Diagnosis of stroke had a statistically significant association with unmet needs (p=0.01). No other
statistically significant associations were detected between any potential confounding categorical or
continuous variables and the presence of unmet spasticity needs (all p values >0.05).
For the 35 participants with identified unmet needs, their general practitioner was informed via
letter of their needs for spasticity management. Six months after this, 31 participants were available
for follow-up as shown in the flow chart in Figure 1. In eight participants (8/31 = 26%), one or more
interventions had been put in place to address the spasticity-related needs identified. Some
participants had multiple interventions, giving a total of 14 new interventions across these eight
participants. These included physiotherapy review (4), new splints (2), new wheelchair (2), new
wheelchair cushion (2), new wheelchair pommel (1), provision of T-roll to assist positioning (1),
referral to rehabilitation medicine clinic (1) and referral to spasticity management clinic (1). In the




This United Kingdom-based cross-sectional study examined the prevalence of unmet need for
spasticity management in care homes in two regions of the East Midlands. This is the first study of
this kind, to our knowledge, to have been conducted in the United Kingdom.
In the 60 participants recruited, there was a high level of spasticity-related need and, furthermore,
the majority of these needs were not being met by current care. Spasticity resulted from stroke in
48% of participants, with the remainder being comprised of individuals with various conditions
including brain injury, multiple sclerosis, cerebral palsy and spinal cord injury. The most frequent
unmet needs relating to spasticity were effective management of skin hygiene and integrity of the
hand, and management of contractures in the upper limb and lower limb. Aggravating factors for
spasticity were present in three quarters of all participants with spasticity. Complications which
could result from spasticity were found including upper and lower limb contractures and pressure
ulcers. Spasticity-related interventions received by study participants targeted some aggravating
factors (for example management of toe nails and pain) or were related to passive care such as
appropriate wheelchair and cushion. There were only a few instances of review by specialist
consultant or the use of botulinum toxin. Highlighting unmet needs to participants’ general
practitioners, in the majority of cases, resulted in no change to participants’ management, such that
after six months, around three quarters of participants still had significant levels of unmet need and
remained at risk of a worsening of spasticity-related complications.
The assessments for association between unmet needs and age and between unmet needs and
number of interventions were both shown to be statistically significant. However, as these were
exploratory analyses, further studies will be required to determine if age or number of interventions
can be used as predictors of number of unmet needs. We feel that the management of spasticity in
care homes is an area that needs further research.
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Unmet need for spasticity management in care home residents has been highlighted in other
studies. Meijer and colleagues in the Netherlands (13) assessed the prevalence, impact and
treatment of spasticity in care home residents with central nervous system disorders. They used the
Modified Ashworth Scale as a measure of spasticity as well as a wide range of bedside tests such as
examination of reflexes, coordination, sensation and motor performance. Participant demographics
were similar between the Meijer study and our study. One third of patients with spasticity in
Meijer’s study were felt to have unmet need, characterised as “treatment indication”. Needs were
classified differently, and the most common indications for treatment were for “easier caring” and
symptom (pain / cramps / spasm) relief, so it is difficult to compare this directly with our study.
Furthermore, Meijer and colleagues suggested specific treatment courses in the 20 patients they
identified with unmet needs, although no data were provided about the outcomes of these
recommendations (13). Directly comparing the two studies, Meijer et al found unmet need in 20/56
(36%) participants versus unmet need in our study of 35/60 (58%). However, caution must be
exercised when comparing care homes between countries, as the term can encompass subacute
care facilities (with integrated rehabilitation) through to geriatric hospitals and hospices, with widely
varying members of staff (24). It is difficult to compare international data without clearer definitions
of the facilities and populations involved.
Care home residents are recognised to have significant difficulties in accessing rehabilitation and
other specialist services (18, 25-27), despite their needs, almost by definition, being greater than
those individuals living in their own homes (19). Care home residents with spasticity often have
cognitive and communication difficulties which make it more difficult for them to express their
needs and consequently they may receive inadequate symptom management unless they are
regularly monitored by experts (28, 29). Our study highlighted that very few participants received
input from specialist consultants or spasticity management services. Botulinum toxin, which is
effective for focal spasticity, was accessed by only 3 participants in our study.
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Consistent pathways need to be developed to ensure residents of care homes with spasticity can
access spasticity management services in a timely manner (30). The United Kingdom Royal College of
Physicians guidelines for management of spasticity in adults (10) highlight the need for treatment at
home for some individuals who are less able to travel, but does not explicitly mention care home
residents – this may benefit from being addressed in future revisions.
Predictive factors could help identify care home residents who may need active spasticity
management, certainly in the post-stroke population. Predictive factors in stroke include severity of
paresis (31) and early presence of spasticity in the upper limb (32). Accurate prediction helps early
treatment and assists rehabilitation planning. The presence of upper limb spasticity at four weeks
post-stroke has shown to be a significant predictor for severe spasticity at twelve months post-
stroke (32). The length of stay of people with stroke in the acute hospital stroke services where this
study was located are as follows: median length of stay in Derby is 7.5 days (interquartile range 3.1 –
19.2 days) and in Nottingham is 7.6 days (interquartile range 1.4 – 24.4 days) (33). Referral to
spasticity services according to presence of spasticity at four weeks would seem to be better placed
coming from the community stroke therapy teams who in-reach into care homes within this
timeframe. Referral could facilitate early access to specialist assessment and botulinum toxin (34). It
is less clear how other client groups (for example people with multiple sclerosis or traumatic brain
injury) would be referred but attention needs to be focussed on this question.
Our study revealed a substantial amount of unmet needs for spasticity management for “passive
function” goals such as maintaining range of movement in limbs and minimising contracture
development (10). Contractures are characterised by a reduction in joint range of motion or an
increase in resistance to passive joint movement (35). Contractures have substantial impact on
quality of life. Immobility predisposes an individual to develop a contracture whether they have a
neurological condition or not (36). Ada et al followed individuals with stroke up to 1 year and
concluded that spasticity can cause contracture (5). However, work by McGibbon et al in traumatic
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brain injury, spinal cord injury and cerebral palsy suggests that there is not is a clear association
between spasticity and contracture (37).
Passive stretches are ineffective to treat contractures (38). Prevention is the preferred option. Input
from specialist spasticity management teams could optimise management. Allison et al suggest that
for people with severe paresis in the arm, education about management of the arm to reduce
secondary complications such as contracture could be an effective intervention (39). In addition,
early targeting of spasticity post-stroke may help minimise contracture development and reduce the
difficulty of caring for the arm over the longer term (39).
Another “passive function” goal with unmet needs found in our study was preserving skin integrity
and maintaining hygiene. There is an increased risk of developing or worsening of existing pressure
ulcers in patients with neurological conditions and patients with contractures (40, 41). It is important
that the vulnerable care home population have access to effective treatments to manage spasticity
to help minimise secondary complications such as pressure ulcers.
There were significant problems around recruitment into this study and we failed to reach our target
sample size. Less than 9% of invited care homes agreed to participate. It was difficult eliciting any
responses from most care homes. There are likely to be a number of factors contributing to this.
Firstly, care homes are stressful places to work, with high levels of under-staffing and staff turnover
(42, 43), so it is perhaps unsurprising that a research study invitation would not be seen as a priority.
In this small study, there was no opportunity for reciprocity, such as training or educational
opportunities for staff, so perceived disadvantages of participation (time consuming, disruptive,
potential for criticism) would not have been countered by any advantages, which may have
encouraged more participation.
After gaining access to care homes, the identification of suitable participants was limited by a lack of
understanding of study criteria by care home staff, who frequently suggested participants who had
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issues of “stiffness” rather than “spasticity”, despite the study team’s best efforts to clarify the
inclusion criteria. It is possible that inviting care home staff to educational days, or providing extra
resources, before the study started might have ameliorated this (36), but in a small study, this was
not feasible.
Following identification of suitable participants, the next barriers were around obtaining consent or
assent. There are high rates of apathy and depression in care home residents, which can make
potential participants less willing to consider participation in a study (44, 45). For those potential
participants without the capacity to consent to participation, identifying and then liaising with next
of kin represented further logistical challenges, and it is possible that consultees may have been less
willing to provide assent to a study where there were no immediately identifiable benefits to their
relative.
These problems are not new or unusual. Conducting research in care homes (46), and particularly
through consultees (47), is recognised to be challenging, although networks are being established to
facilitate future research projects, such as the ENRICH (Enabling Research In Care Homes) toolkit,
and we hope to engage with this for further work. On a positive note, those care homes that did
participate gave us positive feedback – particularly when it was felt that participants’ involvement in
the study had led to improvements in care, such as access to therapy or wheelchair services.
Our study had a number of limitations. The recruitment strategy aimed to gain a representative
sample of care homes. However only a few care homes agreed to be involved. It is possible that the
small number of care homes agreeing to participate may have been more interested or pro-active in
spasticity management, and therefore the results obtained in this study should not be extrapolated
beyond this sample. Our attempt to gain participants from different care homes across the two
regions caused us to limit the total number of participants from each care home to 10. This resulted
in 48% of our sample of participants with spasticity being due to stroke. A different recruitment
strategy would be required for us to gain greater numbers of participants with multiple sclerosis,
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traumatic brain injury, cerebral palsy and other conditions, as potential participants with these
conditions tended to be more predominantly clustered in a smaller number of more specialist care
homes. Taking a larger number from these homes would have included more people with alternative
diagnoses, but would have been less reflective of the “general” care home population.
The design of our study was cross-sectional and therefore gave no indication of the time course of
development of needs and unmet needs. Future research would be valuable to understand the
differing needs for spasticity management along the trajectory of different neurological conditions.
The data collection pro-forma we used was trialled on just a few patients. Ideally, we would have
completed a more formal evaluation but were unable to do this in the timescale of this study. It is
also important to acknowledge that the presence or absence of “unmet needs” relied on the
judgement of the assessing team.
We wrote to the general practitioner of each participant with unmet needs for spasticity
management providing summary information of these needs. It was not feasible to do more than
this within the context of this study. However, a future study would benefit from further
consideration of how to ensure the participants’ needs for spasticity management could be met. In
view of the highly pressured and increasing workloads of general practitioners, the involvement of
the community neuro-rehabilitation therapists responsible for the residents’ care home might be a
good option to consider.
Whilst acknowledging the limitations of our study, the findings indicate a high level of need for
spasticity management in care home residents in two regions of the United Kingdom. Most of these
needs were not being met by current care plans.
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Clinical Messages
 In this sample of care home residents with spasticity in the East Midlands, United Kingdom,
there was a high level of unmet need for spasticity management.
 Most spasticity-related needs remained unmet 6 months after informing participants’
general practitioners of these needs.
 Gaining access to the care home population and identifying suitable study participants
within this population proved very challenging.
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Table 1: Demographic and clinical details of study population of care home residents with spasticity
(n=60)
Demographic details Gender male:female (n) 26:34
Age: median (IQR) 71 (53-84)
Consent, cognition and
dependency
Assent via consultee (n) 26
Abbreviated Mental Test-4 score: median (IQR) 2 (0-4)
Barthel Index*: median (IQR) 2 (0-5)
Clinical details Resistance to Passive Movement score: median (IQR) 22 (9-32)
Presence of muscle spasms (n) 22
Presence of pressure sores (n) 6
Presence of joint contractures (n) 35
Presence of at least one noxious stimulus 45
Mean number of spasticity-related interventions per
participant
8
*note Barthel Index data only available for 58 participants
NB: potential Barthel scores range from 0 (totally dependent) to 10 (totally independent); Resistant
to Passive Movement Score from 0 (no spasticity identified at any joint) to 104 (increased tone
limiting movement to less than ¼ at each joint assessed)
IQR = interquartile range
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Table 2: List of noxious stimuli which are aggravating factors to spasticity and frequency with which
these were found in study participants
Source of noxious
stimulus
Examples Number of participants affected
out of total of 60
Bladder Incontinence / catheter-related
problems
16
Bowel Incontinence / constipation 19
Pain Nociceptive or neuropathic 33
Current infection Urinary tract or chest 5





Table 3: List of spasticity-related interventions screened for and the numbers of participants who
were receiving these interventions at time of assessment
Intervention
category














Spasticity medication (enteral) 23 (38) 0 (0-1.0)
Botulinum toxin injections 3 (5)
Phenol injections 0 (0)
Intrathecal baclofen 0 (0)
Surgical release 0 (0)
Physical
interventions
Muscle stretching programme (at least 1/week) 21 (35) 2 (0 – 3.3)
Positioning programme (in bed and/or chair) 29 (48)
Bed positioning equipment 18 (30)
Splints / orthoses 9 (15)
Pressure relieving hoist sling 14 (23)
District nurse 5 (8)
Community physiotherapist 17 (28)




Bowel management programme 29 (48) 2 (2.0 – 3.0)
Regular analgesia 46 (77)
Bladder care programme 18 (30)
Podiatry review 56 (93)
29
Seating Appropriate seating 48 (80) 3 (2.0 – 3.0)
Appropriate cushion 48 (80)
Wheelchair services 33 (55)
Specialist
review
Specialist spasticity management professional 7 (12) 0 (0 – 1.0)
Tissue viability nurse 6 (10)
Orthotist 6 (10)
Rehabilitation medicine consultant 8 (13)
Stroke physician 1 (2)
Neurologist 4 (7)
Neurosurgeon (e.g. for intrathecal baclofen) 1 (2)
Orthopaedic surgeon (e.g. surgical release) 1 (2)
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Table 4: List of needs for spasticity management and the frequency that these needs were assessed
as being unmet in the study participants
Needs
category






Overall Any need(s) for spasticity
management




Hand 30 (50) 22 (37)
Antecubital fossa 7 (12) 3 (5.0)
Axilla 11 (18) 6 (10)
Groin/perineum 8 (13) 4 (6.7)
Ischial tuberosity, sacrum or greater
trochanter
15 (25) 10 (17)
Neck region 3 (5.0) 2 (3.3)
Dressing Upper limb 34 (57) 3 (5.0)
Lower limb 25 (42) 2 (3.3)
Postural
management
Difficulty positioning in bed 26 (43) 14 (23)
Difficulty sitting in chair or
wheelchair
25 (43) 10 (17)
Pain related
to spasticity
Upper limb 13 (22) 8 (13)
Lower limb 7 (12) 3 (5.0)
Neck region 0 (0) 0 (0)
Contracture Upper limb 37 (62) 26 (43)
Lower limb 30 (50) 17 (28)
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Upper limb function 6 (10) 3 (5.0)
Standing, transferring, walking 10 (17) 8 (13)
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Figure 2: correlations between continuous variables and total numbers of unmet needs identified in
participants.
Spearman’s correlation co-
efficient 0.2336; p 0.028
Pearson’s correlation co-
efficient 0.395; p 0.009
Spearman’s correlation co-
efficient -0.300; p 0.067
Pearson’s correlation co-
efficient -0.364; p 0.027
